238
Q& A
Spiro Sertsis: CCIM
Scott Boyes: MPX
OTC: MPXEF;
CSE: MPX
HVST)
HVST)
P
MPX: We have strong expertise operating profitability through our Health for Life dispensaries and we control all of our operations from seed through to sale. Our management team has the experience and the know how to execute on our strategies; this is critical as the ability to strategically acquire and fold in companies optimally can make or break growth. As well, our focus in the U.S. has been towards the production and sale of high-grade flower, quality concentrates and pharma-grade cannabis-infused derivatives. As the scope of products legally permitted in Canada is expanded by the government, the same focus will be extended to the Canadian consumer. We see the cultivation of millions of sq. ft. of lower grade cannabis flower to be a questionable long-term strategy.
CCIM: At time of writing, MPX has a current market cap of approximately $285M with a share price of around $0.84. You are awaiting a cultivation and sales license for your Bio Cannabis Products Ltd.’s Owen Sound facility and an expanding footprint in the U.S. with your Melting Point Extracts and Health for Life brands. From both a patient perspective, and from an investor’s perspective, why choose MPX?
MPX: Investors should consider MPX for a number of reasons.
First, we’ve proven we can be profitable, through our Nevada and Arizona operations. We have a growing brand presence with both our Health for Life dispensaries and MPX brand. But most importantly, we have a strategy and we have proven that we can execute on it. The U.S. cannabis market is highly fragmented; over the last 18 months, we have demonstrated through various acquisitions that we have the knowledge and capital to successfully roll these companies under the MPX umbrella.
NEWS Feb. 12, 2018 MPX Announces Inclusion in Horizons Emerging Marijuana Growers Index ETF